MST1 and cancer: To improve the clinical benefits of PARPi, we found that targeting STRIPAK to recover or even enhance MST1/2 kinase activity could induce the development of DNA repair defects, regardless of the intrinsic DNA repair machinery, and therefore resensitize cancer cells to PARP inhibition (Supplemental Figure 11B).